chlorambucil,acalabrutinib,obinutuzumab
roche,astrazeneca,gsk
['cll', 'leukemia', 'chlorambucil', 'acalabrutinib', 'obinu', 'leusm']
with roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without #obinutuzumab vs obinutuzumab and #chlorambucil in patients with treatment-na ve chronic lymphocytic #leukemia. #leusm #cll #asco22 
Oncology news and insights from leading researchers and cancer centers.